IBRX Logo

ImmunityBio, Inc. (IBRX) 

NASDAQ
Market Cap
$3.7B
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
567 of 776
Rank in Industry
306 of 433

Largest Insider Buys in Sector

IBRX Stock Price History Chart

IBRX Stock Performance

About ImmunityBio, Inc.

ImmunityBio, Inc., a clinical-stage biotechnology company, develops therapies and vaccines to treat cancers and infectious diseases. It offers immunotherapy and cell therapy platforms, including antibody cytokine fusion proteins, synthetic immunomodulators, vaccine technologies, natural killer cells, and adaptive (T cell) immune systems. The company also develops therapeutic agents, which are in Phase II or III clinical trial for the treatment of liquid and solid tumors, including bladder, pancreatic, and lung cancers, as well as pathogens as …

Insider Activity of ImmunityBio, Inc.

Over the last 12 months, insiders at ImmunityBio, Inc. have bought $0 and sold $0 worth of ImmunityBio, Inc. stock.

On average, over the past 5 years, insiders at ImmunityBio, Inc. have bought $15.1M and sold $8.47M worth of stock each year.

There was no buying activity among insiders over the last 12 months.

The last purchase of 71,915 shares for transaction amount of $198,023 was made by BLASZYK MICHAEL D (director) on 2023‑06‑05.

List of Insider Buy and Sell Transactions, ImmunityBio, Inc.

2023-06-05Purchasedirector
71,915
0.0166%
$2.75$198,023+30.82%
2023-06-02Purchasedirector
25,000
0.006%
$2.83$70,700+31.59%
2023-06-02Purchasedirector
15,000
0.0035%
$2.78$41,700+31.59%
2023-06-01Purchasedirector
7,000
0.0016%
$2.91$20,370+23.81%
2021-10-08PurchaseCEO & President
1,930
0.0005%
$8.81$16,995-38.25%
2021-08-23Saledirector
14,801
0.0035%
$10.12$149,795-45.86%
2021-08-20Saledirector
9,976
0.0025%
$10.00$99,808-41.00%
2021-08-18Saledirector
2,133
0.0006%
$10.03$21,389-36.74%
2021-08-17Saledirector
43,398
0.0112%
$10.12$439,361-41.04%
2021-05-25Saledirector
88,787
0.0237%
$16.18$1.44M-54.64%
2021-05-24Saledirector
21,223
0.0056%
$16.02$340,071-54.46%
2021-05-21Saledirector
14,990
0.0039%
$16.09$241,164-53.43%
2021-02-05SaleSee remarks
22,100
0.0056%
$23.09$510,267-52.76%
2021-02-02SaleSee remarks
82,070
0.0212%
$20.65$1.69M-46.10%
2021-01-28SaleSee remarks
11,304
0.0033%
$20.53$232,121-39.34%
2021-01-27SaleSee remarks
36,626
0.01%
$20.61$754,946-42.76%
2021-01-12SaleChief Financial Officer
16,364
0.004%
$15.00$245,460-26.52%
2021-01-04SaleChief Financial Officer
39,271
0.0102%
$13.62$534,938-6.48%
2020-12-22SaleSee remarks
130,000
0.1231%
$18.05$2.35M-22.23%
2020-12-10Saledirector
42,592
0.0385%
$10.83$461,122+25.09%

Insider Historical Profitability

<0.0001%
SOON-SHIONG PATRICKChairman and CEO
23750750
3.4099%
$5.3220<0.0001%
BLASZYK MICHAEL Ddirector
71915
0.0103%
$5.3210+30.82%
Brennan John Owendirector
15000
0.0022%
$5.3220+31.59%
Clark Wesleydirector
8000
0.0011%
$5.3210+23.81%
Wilson AngelaChief Financial Officer
3265
0.0005%
$5.3210<0.0001%

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
State Street$76.17M2.0514.18M+49.77%+$25.31M<0.01
The Vanguard Group$72.71M1.9613.54M+1.58%+$1.13M<0.01
BlackRock$55.72M1.510.38M-3.13%-$1.8M<0.01
Geode Capital Management$18.7M0.53.48M+3.02%+$547,396.77<0.01
Credit Suisse$8.32M0.221.55M+1.24%+$101,589.660.01
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.